FASTAC fluid treatment system to be installed at Volvo plant in Sweden
Ridgefield, CT. ------ October 24, 2000
Mr. Barry Ressler, Chairman and Chief Executive Officer of Triton Thalassic Technologies, Inc. (T3I), announced today that T3I will be installing its FASTAC fluid treatment system into a Volvo plant in Sweden. FASTAC treatment systems are in use at General Motors engine and powertrain plants in the US. This is the first installation outside of the United States.
T3Is FASTAC system is designed to treat and control bacteria contaminated metalworking fluids in industrial machining operations and significantly reduce, and in some cases eliminate, the need for chemical biocides. Exposure to biocides, which are toxic, has been associated with cancer and non-malignant respiratory issues as well as other health problems. At one transmission plant, the FASTAC system has reduced bacteria levels more than 99.9% compared to the biocide regimen. As a result, this metalworking fluid sump has not required a single biocide addition in the six months the FASTAC system has been operating.
T3I is also planning to install its FASTAC treatment system into pulp and paper mills and food processing plants where strict regulatory restrictions regarding the use of chemical biocides have been mandated. In addition to growing interest in the U.S., the FASTAC technology was introduced at the International Pulp and Paper Symposium sponsored by the Paper Federation of Great Britain in September 2000. We are encouraged by the intial response from the industry.
The FASTAC systems ability to treat opaque fluids with light energy is based on its patented monochromatic light source technology. T3I is currently investigating applications of this technology with blood banks and clinical pathology laboratories. These investigations are targeted at transfusable blood products and the problem of viral and bacterial contamination of the nations (and worlds) blood supply.
The company welcomes prospective customers with fluid contamination questions and challenges to use our convenient inquiry response form.